{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:54:50Z","timestamp":1762502090493,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["ZR2019LZL010"],"award-info":[{"award-number":["ZR2019LZL010"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020MH403"],"award-info":[{"award-number":["ZR2020MH403"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bbrep.2023.101443","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T14:54:49Z","timestamp":1677250489000},"page":"101443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Tuftsin-tailored fusion protein inhibits the growth of circulating gastric tumor cells associated with macrophage phagocytosis"],"prefix":"10.1016","volume":"34","author":[{"given":"Dandan","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2023.101443_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238909082550","article-title":"Tuftsin: its chemistry, biology, and clinical potential","volume":"24","author":"Fridkin","year":"1989","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.bbrep.2023.101443_bib2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00262-014-1604-1","article-title":"Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation, CANCER IMMUNOL IMMUN","volume":"63","author":"Liu","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbrep.2023.101443_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2119\/2007-00018.Khan","article-title":"Tuftsin augments antitumor efficacy of liposomized etoposide against fibrosarcoma in Swiss albino mice","volume":"13","author":"Khan","year":"2007","journal-title":"Mol. Med."},{"key":"10.1016\/j.bbrep.2023.101443_bib4","first-page":"770","article-title":"Targeted drug delivery using tuftsin-bearing liposomes: implications in the treatment of infectious diseases and tumors","volume":"22","author":"Khan","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbrep.2023.101443_bib5","first-page":"5465","article-title":"Treatment effect of tuftsin and antigen peptide combined with immune cells on colorectal cancer","volume":"25","author":"Zou","year":"2019","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.bbrep.2023.101443_bib6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/glia.22972","article-title":"Tuftsin-driven experimental autoimmune encephalomyelitis recovery requires neuropilin-1","volume":"64","author":"Nissen","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.bbrep.2023.101443_bib7","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2011.40.9169","article-title":"Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma","volume":"30","author":"Asgharzadeh","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrep.2023.101443_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ijc.33408","article-title":"Tumor-associated macrophage-targeted therapeutics in ovarian cancer","volume":"149","author":"An","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrep.2023.101443_bib9","doi-asserted-by":"crossref","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrep.2023.101443_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbrep.2023.101443_bib11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class Phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrep.2023.101443_bib12","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma, N","volume":"379","author":"Advani","year":"2018","journal-title":"Engl. J. Med"},{"key":"10.1016\/j.bbrep.2023.101443_bib13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbrep.2023.101443_bib14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00432-014-1814-0","article-title":"Isolation and characterization of circulating tumor cells from human gastric cancer patients","volume":"141","author":"Yuan","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbrep.2023.101443_bib15","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3892\/ijo.2014.2644","article-title":"P-Akt\/miR-200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells","volume":"45","author":"Yuan","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbrep.2023.101443_bib16","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41401-018-0069-8","article-title":"EGFR-targeting, beta-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis","volume":"39","author":"Liu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrep.2023.101443_bib17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrep.2023.101443_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","article-title":"Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication","volume":"28","author":"Theruvath","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrep.2023.101443_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2407-13-202","article-title":"Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker","volume":"13","author":"Liu","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrep.2023.101443_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/acs.jmedchem.0c01530","article-title":"Peptide-drug conjugates with different linkers for cancer therapy","volume":"64","author":"Alas","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrep.2023.101443_bib21","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbrep.2023.101443_bib22","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41374-018-0109-5","article-title":"Enediyne-activated, EGFR-targeted human beta-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma","volume":"98","author":"Liu","year":"2018","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bbrep.2023.101443_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2019.02.002","article-title":"Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma","volume":"448","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrep.2023.101443_bib24","doi-asserted-by":"crossref","first-page":"10547","DOI":"10.2147\/IJN.S276336","article-title":"Tuftsin-bearing liposomes co-encapsulated with doxorubicin and curcumin efficiently inhibit EAC tumor growth in mice","volume":"15","author":"Murugesan","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrep.2023.101443_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246229","article-title":"Cancer therapy targeting CD47\/SIRPalpha","volume":"13","author":"Dizman","year":"2021","journal-title":"Cancers"}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580823000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580823000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:51:23Z","timestamp":1762501883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580823000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":25,"alternative-id":["S2405580823000249"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2023.101443","relation":{},"ISSN":["2405-5808"],"issn-type":[{"type":"print","value":"2405-5808"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuftsin-tailored fusion protein inhibits the growth of circulating gastric tumor cells associated with macrophage phagocytosis","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2023.101443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101443"}}